Literature DB >> 21992553

Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring?

J Lunz1, K M Ruppert, M M Cajaiba, K Isse, C A Bentlejewski, M Minervini, M A Nalesnik, P Randhawa, E Rubin, E Sasatomi, M E de Vera, P Fontes, A Humar, A Zeevi, A J Demetris.   

Abstract

C4d-assisted recognition of antibody-mediated rejection (AMR) in formalin-fixed paraffin-embedded tissues (FFPE) from donor-specific antibody-positive (DSA+) renal allograft recipients prompted study of DSA+ liver allograft recipients as measured by lymphocytotoxic crossmatch (XM) and/or Luminex. XM results did not influence patient or allograft survival, or cellular rejection rates, but XM+ recipients received significantly more prophylactic steroids. Endothelial C4d staining strongly correlates with XM+ (<3 weeks posttransplantation) and DSA+ status and cellular rejection, but not with worse Banff grading or treatment response. Diffuse C4d staining, XM+, DSA+ and ABO- incompatibility status, histopathology and clinical-serologic profile helped establish an isolated AMR diagnosis in 5 of 100 (5%) XM+ and one ABO-incompatible, recipients. C4d staining later after transplantation was associated with rejection and nonrejection-related causes of allograft dysfunction in DSA- and DSA+ recipients, some of whom had good outcomes without additional therapy. Liver allograft FFPE C4d staining: (a) can help classify liver allograft dysfunction; (b) substantiates antibody contribution to rejection; (c) probably represents nonalloantibody insults and/or complete absorption in DSA- recipients and (d) alone, is an imperfect AMR marker needing correlation with routine histopathology, clinical and serologic profiles. Further study in late biopsies and other tissue markers of liver AMR with simultaneous DSA measurements are needed. ©Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21992553     DOI: 10.1111/j.1600-6143.2011.03786.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  12 in total

1.  Quantification of C4d deposition and hepatitis C virus RNA in tissue in cases of graft rejection and hepatitis C recurrence after liver transplantation.

Authors:  Alice Tung Wan Song; Evandro Sobroza de Mello; Venâncio Avancini Ferreira Alves; Norma de Paula Cavalheiro; Carlos Eduardo Melo; Patricia Rodrigues Bonazzi; Fatima Mitiko Tengan; Maristela Pinheiro Freire; Antonio Alci Barone; Luiz Augusto Carneiro D'Albuquerque; Edson Abdala
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-02-13       Impact factor: 2.743

Review 2.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

3.  Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss.

Authors:  Jacqueline G O'Leary; Hugo Kaneku; Anthony J Demetris; John D Marr; S Michelle Shiller; Brian M Susskind; Glenn W Tillery; Paul I Terasaki; Göran B Klintmalm
Journal:  Liver Transpl       Date:  2014-01-02       Impact factor: 5.799

4.  Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features.

Authors:  Jacqueline G O'Leary; S Michelle Shiller; Christopher Bellamy; Michael A Nalesnik; Hugo Kaneku; Linda W Jennings; Kumiko Isse; Paul I Terasaki; Göran B Klintmalm; Anthony J Demetris
Journal:  Liver Transpl       Date:  2014-10       Impact factor: 5.799

5.  Bortezomib for acute antibody-mediated rejection in liver transplantation.

Authors:  F Paterno; M Shiller; G Tillery; J G O'Leary; B Susskind; J Trotter; G B Klintmalm
Journal:  Am J Transplant       Date:  2012-06-08       Impact factor: 8.086

Review 6.  Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

7.  The role of donor-specific HLA alloantibodies in liver transplantation.

Authors:  J G O'Leary; A J Demetris; L S Friedman; H M Gebel; P F Halloran; A D Kirk; S J Knechtle; S V McDiarmid; A Shaked; P I Terasaki; K J Tinckam; S J Tomlanovich; K J Wood; E S Woodle; A A Zachary; G B Klintmalm
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

Review 8.  Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.

Authors:  Antonio Cuadrado; David San Segundo; Marcos López-Hoyos; Javier Crespo; Emilio Fábrega
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

9.  The impact of alloantibodies directed against the second donor on long-term outcomes of repeat liver transplantation.

Authors:  Qingyong Xu; Brad Shrum; Steve Leckie; Anton Skaro; Vivian C McAlister
Journal:  Hepatobiliary Surg Nutr       Date:  2019-06       Impact factor: 7.293

10.  Preoperative selective desensitization of live donor liver transplant recipients considering the degree of T lymphocyte cross-match titer, model for end-stage liver disease score, and graft liver volume.

Authors:  Geun Hong; Nam-Joon Yi; Suk-won Suh; Tae Yoo; Hyeyoung Kim; Min-Su Park; YoungRok Choi; Kyungbun Lee; Kwang-Woong Lee; Myoung Hee Park; Kyung-Suk Suh
Journal:  J Korean Med Sci       Date:  2014-04-25       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.